Summary of the status of biologic medications in Canada

Province	Medication	Disease Type	Status in September, 2012	Status as of August, 2013
British Columbia	Belimumab	Systemic lupus	Under review	Declined
BITUSII COIUIIIDIA	(Benlysta®)	erythematosus	Olider review	Decimed
	Rituximab	Vasculitis	Under review	Listed-CBC
	(Rituxan®)	rascancis	onder review	Listed CDC
	Tocilizumab	Juvenile idiopathic	Under review	Listed-CBC
	(Actemra®)	arthritis		1.0000. 020
Alberta	Belimumab	Systemic lupus	Under review	Under review
	(Benlysta®)	erythematosus		
	Certolizumab	Rheumatoid	Under review	Under review
	pegol (Cimzia®)	arthritis		
	Rituximab	Vasculitis	Under review	Listed-CBC
	(Rituxan®)			
	Tocilizumab	Rheumatoid	Listed-ORC	Listed-CBC
	(Actemra®)	arthritis		
		Juvenile idiopathic	Under review	Listed-CBC
		arthritis		
Saskatchewan	Belimumab	Systemic lupus	Under review	Declined
	(Benlysta®)	erythematosus		
	Certolizumab	Rheumatoid	Under review	Under review
	pegol (Cimzia®)	arthritis		
	Rituximab	Vasculitis	Under review	Listed-CBC
	(Rituxan®)			
	Tocilizumab	Juvenile idiopathic	Under review	Listed-CBC
	(Actemra®)	arthritis		
Manitoba	Abatacept	Juvenile idiopathic	Under review	Under review
	(Orencia®)	arthritis		
	Belimumab	Systemic lupus	Under review	Under review
	(Benlysta®)	erythematosus		
	Certolizumab	Rheumatoid	Under review	Under review
	pegol (Cimzia®)	arthritis		
	Etanercept	Juvenile idiopathic	Unknown	Unknown
	(Enbrel®)	arthritis		
Ontario	Golimumab	Rheumatoid	Under review	Listed-CBC
	(Simponi®)	arthritis		
		Ankylosing	Under review	Listed-CBC
		spondylitis		
	Director 1	Psoriatic arthritis	Under review	Listed-CBC
	Rituximab	Vasculitis	Under review	Under review
	(Rituxan®)	Lucanila (di conti	Hadana 1	Lists of CDC
	Tocilizumab	Juvenile idiopathic	Under review	Listed-CBC
	(Actemra®)	arthritis	Hadana 1	Lists of CDC
	Abatacept	Rheumatoid	Under review	Listed-CBC
	(Orencia®)	arthritis		

	Adalimumab (Humira®)	Juvenile idiopathic arthritis	Not applicable	Listed-CBC
	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Denosumab (Prolla®)	Osteoporosis	Under review	Under review
Quebec	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Under review	Under review
	Rituximab (Rituxan®)	Vasculitis	Under review	Under review
	Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Listed-CBC
New Brunswick	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Declined	Declined
	Infliximab (Remicade®)	Psoriatic arthritis	Declined	Declined
	Rituximab (Rituxan®)	Vasculitis	Under review	Listed-CBC
	Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Listed-CBC
Nova Scotia	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Under review	Under review
	Infliximab (Remicade®)	Ankylosing spondylitis	Under review	Listed-CBC
		Psoriatic arthritis	Declined	Declined
	Rituximab (Rituxan®)	Vasculitis	Under review	Listed-CBC
	Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Listed-CBC
Newfoundland and Labrador	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review
	Certolizumab pegol (Cimzia®)	Rheumatoid arthritis	Under review	Under review
	Infliximab (Remicade®)	Psoriatic arthritis	Declined	Declined
	Rituximab (Rituxan®)	Vasculitis	Under review	Under review
	Tocilizumab (Actemra®)	Juvenile idiopathic arthritis	Under review	Under review
Prince Edward Island	Belimumab (Benlysta®)	Systemic lupus erythematosus	Under review	Under review

	Certolizumab	Rheumatoid	Under review	Listed-CBC
	pegol (Cimzia®)	arthritis	Onder review	Listed CBC
	Denosumab	Osteoporosis	Under review	Under review
	(Prolla®)	Ostcoporosis	Onder review	Officer review
	Infliximab	Psoriatic arthritis	Under review	Under review
	(Remicade®)			
	Rituximab	Vasculitis	Under review	Under review
	(Rituxan®)			
NIHB*	Belimumab	Systemic lupus	Under review	Under review
	(Benlysta®)	erythematosus		
	Certolizumab	Rheumatoid	Declined	Listed-CBC
	pegol (Cimzia®)	arthritis		
	Infliximab	Ankylosing	Declined	Declined
	(Remicade®)	spondylitis		
		Psoriatic arthritis	Declined	Declined
	Rituximab	Vasculitis	Under review	Under review
	(Rituxan®)			
	Tocilizumab	Juvenile idiopathic	Under review	Under review
	(Actemra®)	arthritis		
Yukon	Abatacept	Juvenile idiopathic	Under review	Under review
	(Orencia®)	arthritis		
	Adalimumab	Ankylosing	Under review	Under review
	(Humira®)	spondylitis		
	Belimumab	Systemic lupus	Under review	Under review
	(Benlysta®)	erythematosus		
	Certolizumab	Rheumatoid	Under review	Under review
	pegol (Cimzia®)	arthritis		
	Denosumab	Osteoporosis	Under review	Under review
	(Prolla®)	·		
	Etanercept	Ankylosing	Under review	Under review
	(Enbrel®)	spondylitis		
		Juvenile idiopathic	Under review	Under review
		arthritis		
		Psoriatic arthritis	Under review	Under review
	Golimumab	Rheumatoid	Under review	Under review
	(Simponi®)	arthritis		
		Ankylosing	Under review	Under review
		spondylitis		
		Psoriatic arthritis	Under review	Under review
	Infliximab	Ankylosing	Under review	Under review
	(Remicade®)	spondylitis		
	, ,	Psoriatic arthritis	Under review	Under review
	Rituximab	Vasculitis	Under review	Under review
	(Rituxan®)			
	1 \ /	1	1	
	Tocilizumab	Rheumatoid	Under review	Under review

*Note: People living in the Northwest Territories and Nunavut, who do not have private health insurance, have coverage for those medications listed on the federal Non-Insured Health Benefits (NIHB) formulary.

Definitions

Declined: The formulary does not reimburse patients prescribed this medication.

Listed-CBC: Each province and territory has a process by which medications that are not normally included in the provincial, territorial or federal drug benefit lists are covered (or reimbursed). Approval of this medication is granted on a case-by-case basis.

Listed-ORC: The medication is listed, but the criteria are not supported by medical evidence. Arthritis Consumer Experts considers these overly restrictive criteria (ORC) unacceptable.

Not Applicable: No Notice of Compliance (or NOC) has been issued for this medication for this form of arthritis.

Under Review: This medication has been approved by Health Canada for this disease type and the province is considering whether patients should be reimbursed for it.

Unknown: There is no public information available.